Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)

Tadashi Iida; Yasuyuki Mizutani; Nobutoshi Esaki; Suzanne M. Ponik; Brian M. Burkel; Liang Weng; Keiko Kuwata; Atsushi Masamune; Seiichiro Ishihara; Hisashi Haga; Kunio Kataoka; Shinji Mii; Yukihiro Shiraki; Takuya Ishikawa; Eizaburo Ohno; Hiroki Kawashima; Yoshiki Hirooka; Mitsuhiro Fujishiro; Masahide Takahashi; Atsushi Enomoto

doi:10.1038/s41388-022-02336-4

Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)

Tadashi Iida
, Yasuyuki Mizutani
, Nobutoshi Esaki
, Suzanne M. Ponik
, Brian M. Burkel
, Liang Weng
, Keiko Kuwata
, Atsushi Masamune
, Seiichiro Ishihara
, Hisashi Haga
, Kunio Kataoka
, Shinji Mii
, Yukihiro Shiraki
, Takuya Ishikawa
, Eizaburo Ohno
, Hiroki Kawashima
, Yoshiki Hirooka
, Mitsuhiro Fujishiro
, Masahide Takahashi
, Atsushi Enomoto

Research output: Contribution to journal › Comment/debate › peer-review

2 Citations (Scopus)

Abstract

Affiliation 11 was assigned by mistake to Masahide Takahashi instead of Mitsuhiro Fujishiro The correct affiliation are Mitsuhiro Fujishiro^2,11 Masahide Takahashi¹⁰²Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ¹⁰International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan. ¹¹Present address: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. The original article has been corrected.

Original language	English
Pages (from-to)	3302
Number of pages	1
Journal	Oncogene
Volume	41
Issue number	23
DOIs	https://doi.org/10.1038/s41388-022-02336-4
Publication status	Published - 03-06-2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/s41388-022-02336-4

Fingerprint

Dive into the research topics of 'Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)'. Together they form a unique fingerprint.

Cite this

Iida, T., Mizutani, Y., Esaki, N., Ponik, S. M., Burkel, B. M., Weng, L., Kuwata, K., Masamune, A., Ishihara, S., Haga, H., Kataoka, K., Mii, S., Shiraki, Y., Ishikawa, T., Ohno, E., Kawashima, H., Hirooka, Y., Fujishiro, M., Takahashi, M., & Enomoto, A. (2022). Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9). Oncogene, 41(23), 3302. https://doi.org/10.1038/s41388-022-02336-4

@article{01eb6193ec6c4be9a202f2aeb4ed558f,

title = "Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)",

abstract = "Affiliation 11 was assigned by mistake to Masahide Takahashi instead of Mitsuhiro Fujishiro The correct affiliation are Mitsuhiro Fujishiro2,11 Masahide Takahashi102Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 10International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan. 11Present address: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. The original article has been corrected.",

author = "Tadashi Iida and Yasuyuki Mizutani and Nobutoshi Esaki and Ponik, \{Suzanne M.\} and Burkel, \{Brian M.\} and Liang Weng and Keiko Kuwata and Atsushi Masamune and Seiichiro Ishihara and Hisashi Haga and Kunio Kataoka and Shinji Mii and Yukihiro Shiraki and Takuya Ishikawa and Eizaburo Ohno and Hiroki Kawashima and Yoshiki Hirooka and Mitsuhiro Fujishiro and Masahide Takahashi and Atsushi Enomoto",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2022",

month = jun,

day = "3",

doi = "10.1038/s41388-022-02336-4",

language = "English",

volume = "41",

pages = "3302",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "23",

}

Iida, T, Mizutani, Y, Esaki, N, Ponik, SM, Burkel, BM, Weng, L, Kuwata, K, Masamune, A, Ishihara, S, Haga, H, Kataoka, K, Mii, S, Shiraki, Y, Ishikawa, T, Ohno, E, Kawashima, H, Hirooka, Y, Fujishiro, M, Takahashi, M & Enomoto, A 2022, 'Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)', Oncogene, vol. 41, no. 23, pp. 3302. https://doi.org/10.1038/s41388-022-02336-4

Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9). / Iida, Tadashi; Mizutani, Yasuyuki; Esaki, Nobutoshi et al.
In: Oncogene, Vol. 41, No. 23, 03.06.2022, p. 3302.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction

T2 - Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)

AU - Iida, Tadashi

AU - Mizutani, Yasuyuki

AU - Esaki, Nobutoshi

AU - Ponik, Suzanne M.

AU - Burkel, Brian M.

AU - Weng, Liang

AU - Kuwata, Keiko

AU - Masamune, Atsushi

AU - Ishihara, Seiichiro

AU - Haga, Hisashi

AU - Kataoka, Kunio

AU - Mii, Shinji

AU - Shiraki, Yukihiro

AU - Ishikawa, Takuya

AU - Ohno, Eizaburo

AU - Kawashima, Hiroki

AU - Hirooka, Yoshiki

AU - Fujishiro, Mitsuhiro

AU - Takahashi, Masahide

AU - Enomoto, Atsushi

PY - 2022/6/3

Y1 - 2022/6/3

N2 - Affiliation 11 was assigned by mistake to Masahide Takahashi instead of Mitsuhiro Fujishiro The correct affiliation are Mitsuhiro Fujishiro2,11 Masahide Takahashi102Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 10International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan. 11Present address: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. The original article has been corrected.

AB - Affiliation 11 was assigned by mistake to Masahide Takahashi instead of Mitsuhiro Fujishiro The correct affiliation are Mitsuhiro Fujishiro2,11 Masahide Takahashi102Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 10International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan. 11Present address: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85129547248

UR - https://www.scopus.com/pages/publications/85129547248#tab=citedBy

U2 - 10.1038/s41388-022-02336-4

DO - 10.1038/s41388-022-02336-4

M3 - Comment/debate

C2 - 35508544

AN - SCOPUS:85129547248

SN - 0950-9232

VL - 41

SP - 3302

JO - Oncogene

JF - Oncogene

IS - 23

ER -

Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L et al. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9). Oncogene. 2022 Jun 3;41(23):3302. doi: 10.1038/s41388-022-02336-4

Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Oncogene, (2022), 41, 19, (2764-2777), 10.1038/s41388-022-02288-9)

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this